How do you translate strategy into an actionable late lifecycle plan?
Loss of exclusivity (LOE) fundamentally changes how value is created, assessed, and sustained. As competition intensifies and pricing pressure increases, pharmaceutical brands can no longer rely on clinical differentiation alone. Instead, success in the late lifecycle depends on a deliberate, structured approach to how value is protected, evolved and delivered in-market.
In earlier parts of our late lifecycle (LLC) management series, we explored the dynamics that shape post‑LOE environments and how archetyping can help global teams set a clear strategic direction while allowing for local market variation.
But, the critical question remains: how do global and local teams translate strategy into an actionable, coherent late lifecycle plan?
Introducing the PSVA Framework
Through our work across many different assets and markets, we consistently see late lifecycle tactics cluster into four interconnected categories: Product, Solution, Value, and Asset optimization. Together, these form the PSVA framework.
This PDF guide reveals:
🔹 What is the PSVA framework – and why is it useful?
🔹 A closer look at each component and the late lifecycle tactics available
🔹 10 pharma case studies illustrating real-world examples
Fill in the form below for instant access →
Access the Toolkit Now
Authors and contributors
